(UroToday.com) The 2021 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium included a presentation by Dr. Ashley Ross discussing the use of genomics to guide treatment decisions in post-prostatectomy patients. Dr. Ross notes that a recent systematic review assessed the clinical utility of the Decipher® genomic classifier recently published in European Urology.1 This genomic classifier assesses 22 genes representing multiple oncologic pathways, is heavily validated, and is independently prognostic of oncologic outcomes. In this systematic review, there were 42 studies and 30,407 patients included. In 32 studies (n=12,600), the genomic classifier was independently prognostic for all study endpoints (adverse pathology, biochemical failure, metastasis, and cancer-specific and overall survival) and improved the discrimination over standard of care in 24 studies (n=8,543):